Applications of monoclonal antibodies for the treatment of hematological malignancies

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 207-220

  Migkou, Magda ^a   Dimopoulos, Meletios Athanassios ^a   Gavriatopoulou, Maria ^a   Terpos, Evangelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute leukemia; Lymphoma; Monoclonal antibodies; Multiple myeloma; Myelodysplastic syndrome

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALPHA2A INTERFERON; AMSACRINE; BEVACIZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HU 1D 10; IDARUBICIN; INFLIXIMAB; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; TIOGUANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LUNG INJURY; ALLERGIC REACTION; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBIOTIC PROPHYLAXIS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DISEASE CONTROL; DISEASE COURSE; DISEASE FREE SURVIVAL; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; ERADICATION THERAPY; FEBRILE NEUTROPENIA; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; FUNGAL PNEUMONIA; GENE DELETION; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; INFECTION RISK; LARGE CELL LYMPHOMA; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; LYMPHADENOPATHY; LYMPHOMA CELL; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; POINT MUTATION; PROLYMPHOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA; RASH; RELAPSE; REVIEW; RISK REDUCTION; SEPSIS; SEPTICEMIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SPLENOMEGALY; T CELL DEPLETION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS REACTIVATION; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN;

EID: 66149084078     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802650581     Document Type: Review

References (107)

1. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-626
2. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002;20:215-229 (Pubitemid 34507438)
3. Coiffier B. Monoclonal antibody as therapy for malignant lymphomas. C R Biol 2006;329:241-254
4. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002;99:754-758 (Pubitemid 34525533)
5. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to front-line R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-2725 (Pubitemid 44777009)
6. Farag SS, Flinn I, Modali R, et al. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103:1472-1474 (Pubitemid 38168664)
7. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement- mediated cell lysis. Blood 2000;95:3900-3908 (Pubitemid 30412866)
8. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003;22:7359-7368
9. Mclaughlin P, Grillo-lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833 (Pubitemid 28363048)
10. Davis TA, White CA, Grillo-lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857 (Pubitemid 29269257)
11. Davis TA, Grillo-lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143 (Pubitemid 30677093)
12. Lemieux B, Bouafia F, Thieblemont C, et al. Second treatment with rituximab in B-cell non Hodgkin's lymphoma: Efficacy and toxicity on 41 patients treated at CHU Lyon Sud. Hematol J 2004;5:467-471
13. Ghielmini M, Schmitz SFH, Sergio B, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule. Blood 2004;103:4416-4423
14. Piro LD, White CA, Grillo-lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999;10:655-661 (Pubitemid 29342370)
15. Cartron G, Solal-celigny P. Maintenance therapy for low-grade lymphomas: has the time come? Curr Opin Oncol 2007;19:425-432
16. Hainsworth JD, Meng C, Spigel DR, et al. Long-term follow-up of patients with follicular lymphoma (FL) treated with two years of maintenance rituximab[Abstract]. Blood 2006:108:2754
17. Buske C, Weigert O, Dreyling M. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006;91:104-112 (Pubitemid 43239532)
18. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 2001;97:101-106
19. Colombat P, Brousse N, Morschhauser F, et al. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/up) of 7 years [abstract]. Blood 2006;108:147a-148a.
20. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002;20:4261-4267
21. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular Grade I Non-Hodgkin's Lymphoma: A Phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23:1103-1108 (Pubitemid 46202265)
22. Czuczman MS, Grillo-lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276 (Pubitemid 29022402)
23. Salles G, Mounier N, de Guibert, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL-2000 study. Blood 2008;26:440-446
24. Herold M, Pasold R, Srock S, et al. Results of a prospective randomized open label phase-iii study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle-cell lymphoma. Blood 2004;104:169a
25. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-1423
26. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood 2005;106:3725-3732
27. Foran JM, Rohatiner AZS, Cunningham D, et al. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small b-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324 (Pubitemid 30056420)
28. Treon SP, Agus TB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001;(24):272-279 (Pubitemid 32479719)
29. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002;(3):163-166 (Pubitemid 36113687)
30. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333 (Pubitemid 34441660)
31. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle-cell lymphomas - results of a prospective randomized study of the German Low-Grade Lymphoma study group (GLSG). Blood 2004;104:3064-3071
32. Economopoulos T, Psyrri A, Fountzilas G, et al. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. Leuk Lymphoma 2008;49:68-74 (Pubitemid 351164222)
33. Morgner A, Schmelz R, Thiede C, et al. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007;13:3554-3566 (Pubitemid 47162262)
34. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535 (Pubitemid 41295078)
35. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood 1998;92:1927-1932 (Pubitemid 28446681)
36. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242 (Pubitemid 34438862)
37. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397 (Pubitemid 32112850)
38. Feugier P, Van Hoof a, Sebban C, et al. Long-term results of the R-CHOP Study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126 (Pubitemid 46211317)
39. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391
40. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2005;24:3121-3127
41. Abbott BL. Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. Oncologist 2006;11;21-30 (Pubitemid 43152683)
42. O'brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-2170
43. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent Rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-1751
44. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-3120 (Pubitemid 35217057)
45. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712(CALGB 9712). Blood 2003;101:6-14 (Pubitemid 36025880)
46. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53 (Pubitemid 40053062)
47. Keating MJ, O'brien S, Albita M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088 (Pubitemid 46211313)
48. Wierda W, O'brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078 (Pubitemid 46211312)
49. Wiestner A. More ZAP for chronic lymphocytic leukemia. Blood 2005;105(5):1839-40Mar 1 (Pubitemid 40731753)
50. Castro JE, Sandoval-sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-2053
51. Ginaldi G, Hamblin, et al. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to CAMPATH-1H. Leuk Res 1998;22:185-191 (Pubitemid 28185349)
52. Dighier G, Hamblin TJ. Chronic lymphocytic leukemia. Lancet 2008;371:1017-1029
53. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-1574 (Pubitemid 27167394)
54. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of Alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561 (Pubitemid 34534522)
55. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-3897 (Pubitemid 35050844)
56. Osterborg A, Fassas AS, Anagnostopoulos A, et al. Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukemia. Br J Haematol 1996;93:151-153
57. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-773
58. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623
59. O'brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-2663
60. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87:695-700 (Pubitemid 34787139)
61. Montillo M, Tedeschi A, Miqueleiz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337-2342 (Pubitemid 46630666)
62. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after Alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971-2979 (Pubitemid 46224116)
63. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogues in chronic B-cell leukemias. Blood 1995;85:1580-1589
64. Cordone I, Masi S, Mauro FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998;91:4342-4349 (Pubitemid 28261999)
65. Lozanski G, Heeremana FLINN, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004;103:3278-3281 (Pubitemid 38525651)
66. Stilngerbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. NEJM 2002;347:452-453 (Pubitemid 34851846)
67. Elter T, Borchman P, Schulz H, et al. Fludarabine in combination with Alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. J Clin Oncol 2005;23:7024-7031 (Pubitemid 46260289)
68. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245-2247 (Pubitemid 34525514)
69. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110-2118
70. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667-2672 (Pubitemid 27289899)
71. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98:1721-1726
72. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2001;20:205-213
73. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphoma: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257-3263
74. Stasi R, Evangelista ML, Buccisano F, et al. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 2008;34:49-60 (Pubitemid 351168609)
75. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-1452 (Pubitemid 41356159)
76. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-1496 (Pubitemid 32708610)
77. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;(99):4343-4349 (Pubitemid 34627199)
78. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005;19:1768-1773
79. Nabhan C, Rundhaugen LM, Riley MB, et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005;(29):53-57
80. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007;21(1):66-71 (Pubitemid 44921836)
81. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;(97):1481-1487 (Pubitemid 36297778)
82. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-4283 (Pubitemid 37494084)
83. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004;(89):950-956
84. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial [abstract 13]. Blood 2006;108:
85. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002;50:497-500 (Pubitemid 35435529)
86. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90 (Pubitemid 36057028)
87. Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887-891 (Pubitemid 36809083)
88. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27:893-897 (Pubitemid 36809084)
89. Chevallier P, Roland V, Mahé B, et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2005;29:1003-1007 (Pubitemid 40982594)
90. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138:186-195 (Pubitemid 46976329)
91. Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005;19:1306-1311 (Pubitemid 41136319)
92. Lo-coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;(104):1995-1999 (Pubitemid 39297848)
93. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;(99):4222-4224 (Pubitemid 35332070)
94. Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007;(109):1355-1359 (Pubitemid 46466562)
95. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma (NHL). J Clin Oncol 2003;21:3051-3059 (Pubitemid 46606284)
96. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-5334 (Pubitemid 39100467)
97. Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-4398 (Pubitemid 46207013)
98. Advani R, Forero-torres A, Furman RR, et al. SGN-40 (anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin's lymphoma: evidence of antitumor activity from a phase I study. Blood 2006;108:209a
99. Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 2008;111:1594-1602 (Pubitemid 351213450)
100. Gotlib J, Jamieson CHM, List A, et al. Phase II study of bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results [abstract]. Blood 2003;102:425a
101. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007;110:1098-1104 (Pubitemid 47281403)
102. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006;(12):1221-1228 (Pubitemid 43342512)
103. Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008:111(3);5486-5495
104. Coiffier B, Stefane L, Pedersen LM, et al. Safety and efficacy of ofatuzumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008:111;1094-1100 (Pubitemid 351213387)
105. Kipriyanov SM, Moldenhauer G, Strauss G, et al. Bispecific CD3 x CD19 diabody for T cell- mediated lysis of malignant human B cells. Int J Cancer 1998;77:763-772 (Pubitemid 28341395)
106. Manzke O, Tesch H, Borchmann P, et al. Locoregional treatment of low-grabe B-cell lymphoma with CD3 x CD19 bispecific antibodies and CD 28 costimulation: I. Clinical phase I evaluation. Int J Cancer 2001;91:508-515
107. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T-cell engaging antibody. Science 2008;321(5891):974-977